_id
69105530ccc777a4e85d55b9
Ticker
CRTHF
Name
CARsgen Therapeutics Holdings Limited
Exchange
PINK
Address
Building 2, Shanghai, China
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.carsgen.com
Description
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of R/R MM, relapsed/refractory primary plasma cell leukemia (R/R pPCL), relapsed/refractory plasma cell leukemia (R/R PCL), and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT059X, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R/ MM and R/R PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2114 that are in the pre-clinical stage for the treatment of solid tumors; and KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence. The company was founded in 2014 and is headquartered in Shanghai, China.
Last Close
2.2
Volume
200
Current Price
1.72
Change
0
Last Updated
2026-01-02T12:01:40.631Z
Image
-
Ipo Date
-
Market Cap
955669888
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9986666666666667
Sentiment Sources
3
Current Quarter
2019-04-30
Revenue
250950000
Cost Of Revenue
200800000
Gross Profit
50150000
Operating Expenses
215550000
Operating Income
35400000
Interest Expense
3550000
Pretax Income
32200000
Net Income
25950000
Eps
-
Dividends Per Share
28000000
Shares Outstanding
547850155
Income Tax Expense
6250000
EBITDA
-
Operating Margin
14.106395696353854
Total Other Income Expense Net
-3200000
Cash
185400000
Short Term Investments
0
Receivables
129000000
Inventories
1183900000
Total Current Assets
1500800000
Property Plant Equipment
5400000
Total Assets
1617400000
Payables
344800000
Short Term Debt
0
Long Term Debt
251800000
Total Liabilities
756600000
Equity
860800000
Bs_currency_symbol
USD
Depreciation
550000
Change In Working Capital
-
Cash From Operations
-12800000
Capital Expenditures
850000
Cash From Investing
300000
Cash From Financing
13050000
Net Change In Cash
550000
Cf_currency_symbol
USD
PE
-
PB
-
ROE
3.0146375464684017
ROA
1.6044268579201186
FCF
-13650000
Fcf Percent
-0.05439330543933055
Piotroski FScore
2
Health Score
37
Deep Value Investing Score
2.5
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
6.8
Garp Investing Score
2
Growth Investing Score
1
Momentum Investing Score
5
Net Net Investing Score
1
Quality Investing Score
5
Value Investing Score
2.5
Quarters > 0 > quarter
2019-04-30
Quarters > 0 > income Statement > revenue
250950000
Quarters > 0 > income Statement > cost Of Revenue
200800000
Quarters > 0 > income Statement > gross Profit
50150000
Quarters > 0 > income Statement > operating Expenses
215550000
Quarters > 0 > income Statement > operating Income
35400000
Quarters > 0 > income Statement > interest Expense
3550000
Quarters > 0 > income Statement > pretax Income
32200000
Quarters > 0 > income Statement > net Income
25950000
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
28000000
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
6250000
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
14.106395696353854
Quarters > 0 > income Statement > total Other Income Expense Net
-3200000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
185400000
Quarters > 0 > balance Sheet > short Term Investments
0
Quarters > 0 > balance Sheet > receivables
129000000
Quarters > 0 > balance Sheet > inventories
1183900000
Quarters > 0 > balance Sheet > total Current Assets
1500800000
Quarters > 0 > balance Sheet > property Plant Equipment
5400000
Quarters > 0 > balance Sheet > total Assets
1617400000
Quarters > 0 > balance Sheet > payables
344800000
Quarters > 0 > balance Sheet > short Term Debt
0
Quarters > 0 > balance Sheet > long Term Debt
251800000
Quarters > 0 > balance Sheet > total Liabilities
756600000
Quarters > 0 > balance Sheet > equity
860800000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
25950000
Quarters > 0 > cash Flow > depreciation
550000
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-12800000
Quarters > 0 > cash Flow > capital Expenditures
850000
Quarters > 0 > cash Flow > cash From Investing
300000
Quarters > 0 > cash Flow > cash From Financing
13050000
Quarters > 0 > cash Flow > net Change In Cash
550000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
3.0146375464684017
Quarters > 0 > ratios > ROA
1.6044268579201186
Quarters > 0 > ratios > FCF
-13650000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
-0.05439330543933055
Quarters > 0 > health Score
37
Quarters > 1 > quarter
2019-01-31
Quarters > 1 > income Statement > revenue
250950000
Quarters > 1 > income Statement > cost Of Revenue
200800000
Quarters > 1 > income Statement > gross Profit
50150000
Quarters > 1 > income Statement > operating Expenses
215550000
Quarters > 1 > income Statement > operating Income
35400000
Quarters > 1 > income Statement > interest Expense
3550000
Quarters > 1 > income Statement > pretax Income
32200000
Quarters > 1 > income Statement > net Income
25950000
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
28000000
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
6250000
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
14.106395696353854
Quarters > 1 > income Statement > total Other Income Expense Net
-3200000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
185400000
Quarters > 1 > balance Sheet > short Term Investments
0
Quarters > 1 > balance Sheet > receivables
129000000
Quarters > 1 > balance Sheet > inventories
1183900000
Quarters > 1 > balance Sheet > total Current Assets
1500800000
Quarters > 1 > balance Sheet > property Plant Equipment
5400000
Quarters > 1 > balance Sheet > total Assets
1617400000
Quarters > 1 > balance Sheet > payables
344800000
Quarters > 1 > balance Sheet > short Term Debt
0
Quarters > 1 > balance Sheet > long Term Debt
251800000
Quarters > 1 > balance Sheet > total Liabilities
756600000
Quarters > 1 > balance Sheet > equity
860800000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
25950000
Quarters > 1 > cash Flow > depreciation
550000
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-12800000
Quarters > 1 > cash Flow > capital Expenditures
850000
Quarters > 1 > cash Flow > cash From Investing
300000
Quarters > 1 > cash Flow > cash From Financing
13050000
Quarters > 1 > cash Flow > net Change In Cash
550000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
3.0146375464684017
Quarters > 1 > ratios > ROA
1.6044268579201186
Quarters > 1 > ratios > FCF
-13650000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
-0.05439330543933055
Quarters > 1 > health Score
37
Quarters > 2 > quarter
2018-10-31
Quarters > 2 > income Statement > revenue
331150000
Quarters > 2 > income Statement > cost Of Revenue
259700000
Quarters > 2 > income Statement > gross Profit
71450000
Quarters > 2 > income Statement > operating Expenses
277250000
Quarters > 2 > income Statement > operating Income
53900000
Quarters > 2 > income Statement > interest Expense
3650000
Quarters > 2 > income Statement > pretax Income
50800000
Quarters > 2 > income Statement > net Income
40950000
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
14350000
Quarters > 2 > income Statement > shares Outstanding
-
Quarters > 2 > income Statement > income Tax Expense
9850000
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
16.276611807338064
Quarters > 2 > income Statement > total Other Income Expense Net
-3100000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
184300000
Quarters > 2 > balance Sheet > short Term Investments
0
Quarters > 2 > balance Sheet > receivables
93000000
Quarters > 2 > balance Sheet > inventories
1186200000
Quarters > 2 > balance Sheet > total Current Assets
1467700000
Quarters > 2 > balance Sheet > property Plant Equipment
4800000
Quarters > 2 > balance Sheet > total Assets
1577400000
Quarters > 2 > balance Sheet > payables
124400000
Quarters > 2 > balance Sheet > short Term Debt
0
Quarters > 2 > balance Sheet > long Term Debt
168300000
Quarters > 2 > balance Sheet > total Liabilities
698800000
Quarters > 2 > balance Sheet > equity
878600000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
40950000
Quarters > 2 > cash Flow > depreciation
550000
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
60250000
Quarters > 2 > cash Flow > capital Expenditures
800000
Quarters > 2 > cash Flow > cash From Investing
550000
Quarters > 2 > cash Flow > cash From Financing
-19600000
Quarters > 2 > cash Flow > net Change In Cash
41200000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
-
Quarters > 2 > ratios > ROE
4.660824038242659
Quarters > 2 > ratios > ROA
2.596044123240776
Quarters > 2 > ratios > FCF
59450000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.17952589460969348
Quarters > 2 > health Score
57
Quarters > 3 > quarter
2018-07-31
Quarters > 3 > income Statement > revenue
331150000
Quarters > 3 > income Statement > cost Of Revenue
259700000
Quarters > 3 > income Statement > gross Profit
71450000
Quarters > 3 > income Statement > operating Expenses
277250000
Quarters > 3 > income Statement > operating Income
53900000
Quarters > 3 > income Statement > interest Expense
3650000
Quarters > 3 > income Statement > pretax Income
50800000
Quarters > 3 > income Statement > net Income
40950000
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
14350000
Quarters > 3 > income Statement > shares Outstanding
-
Quarters > 3 > income Statement > income Tax Expense
9850000
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
16.276611807338064
Quarters > 3 > income Statement > total Other Income Expense Net
-3100000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
184300000
Quarters > 3 > balance Sheet > short Term Investments
0
Quarters > 3 > balance Sheet > receivables
93000000
Quarters > 3 > balance Sheet > inventories
1186200000
Quarters > 3 > balance Sheet > total Current Assets
1467700000
Quarters > 3 > balance Sheet > property Plant Equipment
4800000
Quarters > 3 > balance Sheet > total Assets
1577400000
Quarters > 3 > balance Sheet > payables
124400000
Quarters > 3 > balance Sheet > short Term Debt
0
Quarters > 3 > balance Sheet > long Term Debt
168300000
Quarters > 3 > balance Sheet > total Liabilities
698800000
Quarters > 3 > balance Sheet > equity
878600000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
40950000
Quarters > 3 > cash Flow > depreciation
550000
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
60250000
Quarters > 3 > cash Flow > capital Expenditures
800000
Quarters > 3 > cash Flow > cash From Investing
550000
Quarters > 3 > cash Flow > cash From Financing
-19600000
Quarters > 3 > cash Flow > net Change In Cash
41200000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
4.660824038242659
Quarters > 3 > ratios > ROA
2.596044123240776
Quarters > 3 > ratios > FCF
59450000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.17952589460969348
Quarters > 3 > health Score
57
Annuals > 0 > quarter
2024-10-31
Annuals > 0 > income Statement > revenue
39425000
Annuals > 0 > income Statement > cost Of Revenue
24678000
Annuals > 0 > income Statement > gross Profit
14747000
Annuals > 0 > income Statement > operating Expenses
613129000
Annuals > 0 > income Statement > operating Income
-573704000
Annuals > 0 > income Statement > interest Expense
5713000
Annuals > 0 > income Statement > pretax Income
-797786000
Annuals > 0 > income Statement > net Income
-798132000
Annuals > 0 > income Statement > eps
-1.4527076745602598
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
549409915
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-1455.1781864299303
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > income Statement > currency_symbol
CNY
Annuals > 0 > balance Sheet > cash
1479058000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
8768000
Annuals > 0 > balance Sheet > inventories
6926000
Annuals > 0 > balance Sheet > total Current Assets
1530275000
Annuals > 0 > balance Sheet > property Plant Equipment
118384000
Annuals > 0 > balance Sheet > total Assets
1673034000
Annuals > 0 > balance Sheet > payables
-
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
68850000
Annuals > 0 > balance Sheet > total Liabilities
616327000
Annuals > 0 > balance Sheet > equity
1056707000
Annuals > 0 > balance Sheet > currency_symbol
CNY
Annuals > 0 > cash Flow > net Income
-798132000
Annuals > 0 > cash Flow > depreciation
79555000
Annuals > 0 > cash Flow > change In Working Capital
53093000
Annuals > 0 > cash Flow > cash From Operations
-409690000
Annuals > 0 > cash Flow > capital Expenditures
19574000
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
-
Annuals > 0 > cash Flow > net Change In Cash
-378711000
Annuals > 0 > cash Flow > currency_symbol
CNY
Annuals > 0 > ratios > PE
-1.4527076745602598
Annuals > 0 > ratios > PB
0.9069596924464397
Annuals > 0 > ratios > ROE
-75.53011383477161
Annuals > 0 > ratios > ROA
-47.70566527637812
Annuals > 0 > ratios > FCF
-429264000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-10.888116677235256
Annuals > 0 > health Score
29
Annuals > 1 > quarter
2023-10-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
0
Annuals > 1 > income Statement > gross Profit
0
Annuals > 1 > income Statement > operating Expenses
784677000
Annuals > 1 > income Statement > operating Income
-784677000
Annuals > 1 > income Statement > interest Expense
4664000
Annuals > 1 > income Statement > pretax Income
-747387000
Annuals > 1 > income Statement > net Income
-747794000
Annuals > 1 > income Statement > eps
-1.3419771833658078
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
557233021
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > income Statement > currency_symbol
CNY
Annuals > 1 > balance Sheet > cash
1849752000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
0
Annuals > 1 > balance Sheet > inventories
683000
Annuals > 1 > balance Sheet > total Current Assets
1873088000
Annuals > 1 > balance Sheet > property Plant Equipment
356234000
Annuals > 1 > balance Sheet > total Assets
2257214000
Annuals > 1 > balance Sheet > payables
-
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
0
Annuals > 1 > balance Sheet > total Liabilities
455514000
Annuals > 1 > balance Sheet > equity
1801700000
Annuals > 1 > balance Sheet > currency_symbol
CNY
Annuals > 1 > cash Flow > net Income
-747794000
Annuals > 1 > cash Flow > depreciation
87395000
Annuals > 1 > cash Flow > change In Working Capital
211375000
Annuals > 1 > cash Flow > cash From Operations
-454935000
Annuals > 1 > cash Flow > capital Expenditures
9549000
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
-
Annuals > 1 > cash Flow > net Change In Cash
-437826000
Annuals > 1 > cash Flow > currency_symbol
CNY
Annuals > 1 > ratios > PE
-1.3419771833658078
Annuals > 1 > ratios > PB
0.5395111737983016
Annuals > 1 > ratios > ROE
-41.504912027529556
Annuals > 1 > ratios > ROA
-33.129069729321195
Annuals > 1 > ratios > FCF
-464484000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
33
Annuals > 2 > quarter
2022-10-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
0
Annuals > 2 > income Statement > gross Profit
0
Annuals > 2 > income Statement > operating Expenses
802281000
Annuals > 2 > income Statement > operating Income
-802281000
Annuals > 2 > income Statement > interest Expense
15521000
Annuals > 2 > income Statement > pretax Income
-890952000
Annuals > 2 > income Statement > net Income
-892247000
Annuals > 2 > income Statement > eps
-1.6076833225429146
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
554989274
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
CNY
Annuals > 2 > balance Sheet > cash
2268036000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
0
Annuals > 2 > balance Sheet > total Current Assets
2300639000
Annuals > 2 > balance Sheet > property Plant Equipment
436863000
Annuals > 2 > balance Sheet > total Assets
2762819000
Annuals > 2 > balance Sheet > payables
-
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
2523000
Annuals > 2 > balance Sheet > total Liabilities
289645000
Annuals > 2 > balance Sheet > equity
2473174000
Annuals > 2 > balance Sheet > currency_symbol
CNY
Annuals > 2 > cash Flow > net Income
-892247000
Annuals > 2 > cash Flow > depreciation
81533000
Annuals > 2 > cash Flow > change In Working Capital
43482000
Annuals > 2 > cash Flow > cash From Operations
-643048000
Annuals > 2 > cash Flow > capital Expenditures
138614000
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
-
Annuals > 2 > cash Flow > net Change In Cash
1507428000
Annuals > 2 > cash Flow > currency_symbol
CNY
Annuals > 2 > ratios > PE
-1.6076833225429146
Annuals > 2 > ratios > PB
0.3914497279874364
Annuals > 2 > ratios > ROE
-36.07700064775062
Annuals > 2 > ratios > ROA
-32.2948046904267
Annuals > 2 > ratios > FCF
-781662000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
33
Annuals > 3 > quarter
2021-10-31
Annuals > 3 > income Statement > revenue
25813000
Annuals > 3 > income Statement > cost Of Revenue
0
Annuals > 3 > income Statement > gross Profit
25813000
Annuals > 3 > income Statement > operating Expenses
613039000
Annuals > 3 > income Statement > operating Income
-587226000
Annuals > 3 > income Statement > interest Expense
10869000
Annuals > 3 > income Statement > pretax Income
-4736778000
Annuals > 3 > income Statement > net Income
-4744423000
Annuals > 3 > income Statement > eps
-8.359670437466354
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
567537086
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-2274.923488164878
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > income Statement > currency_symbol
CNY
Annuals > 3 > balance Sheet > cash
691284000
Annuals > 3 > balance Sheet > short Term Investments
2315654000
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
3070853000
Annuals > 3 > balance Sheet > property Plant Equipment
384766000
Annuals > 3 > balance Sheet > total Assets
3505635000
Annuals > 3 > balance Sheet > payables
-
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
7375000
Annuals > 3 > balance Sheet > total Liabilities
508975000
Annuals > 3 > balance Sheet > equity
2996660000
Annuals > 3 > balance Sheet > currency_symbol
CNY
Annuals > 3 > cash Flow > net Income
-4744423000
Annuals > 3 > cash Flow > depreciation
52446000
Annuals > 3 > cash Flow > change In Working Capital
13379000
Annuals > 3 > cash Flow > cash From Operations
-512322000
Annuals > 3 > cash Flow > capital Expenditures
178453000
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
-
Annuals > 3 > cash Flow > net Change In Cash
-309611000
Annuals > 3 > cash Flow > currency_symbol
CNY
Annuals > 3 > ratios > PE
-8.359670437466354
Annuals > 3 > ratios > PB
0.33037171144487526
Annuals > 3 > ratios > ROE
-158.32370038643023
Annuals > 3 > ratios > ROA
-135.3370502063107
Annuals > 3 > ratios > FCF
-690775000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-26.760740712044317
Annuals > 3 > health Score
34
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
3.0146375464684017
Profitability > metrics > ROA
1.7290778251599148
Profitability > metrics > Net Margin
0.10340705319784818
Profitability > final Score
27
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.8789498141263941
Risk > metrics > Interest Coverage
9.971830985915492
Risk > final Score
88
Risk > verdict
Low
Liquidity > metrics > Current Ratio
4.352668213457076
Liquidity > metrics > Quick Ratio
0.9190835266821346
Liquidity > final Score
96
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
27
Prev Profitabilities > 1
36
Prev Profitabilities > 2
36
Prev Risks > 0
88
Prev Risks > 1
88
Prev Risks > 2
88
Prev Liquidities > 0
96
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:39:34.488Z
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of R/R MM, relapsed/refractory primary plasma cell leukemia (R/R pPCL), relapsed/refractory plasma cell leukemia (R/R PCL), and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT059X, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R/ MM and R/R PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2114 that are in the pre-clinical stage for the treatment of solid tumors; and KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence. The company was founded in 2014 and is headquartered in Shanghai, China.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2019-04-30)
Health Score
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of CARsgen Therapeutics Holdings Limited
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2019-04-30)
(Last Updated 2019-04-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2019-04-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2019-04-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.